NR2F6 and non-small cell lung carcinoma: Furthermore, evaluating tumor-infiltrating lymphocytes from non-small cell lung cancer (NSCLC) patients’ biopsies provides substantial preclinical evidence that NR2F6 overexpression at the tumor niche produces effector T cells unable to mount a robust immune response against malignancy (39).